Search research articles
Contact Us
Filters
Showing results (51-60 of 136) with videos related to
Page
of 14
Sort By:
Advances in Therapy
|
July 11, 2024
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Claire N Harrison, Alessandro M Vannucchi, Christian Recher, et al.
Emerging Infectious Diseases
|
July 22, 2015
Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
Suzanne Tavitian, Jean-Marie Peron, Françoise Huguet, et al.
Haematologica
|
July 7, 2017
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients
Etienne De Clara, Morgane Gourvest, Hanjing Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, James S Blachly, Armin Ghobadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Experimental Hematology & Oncology
|
September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Mary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
American Journal of Hematology
|
September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO Study
Corentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A Pollyea, Keith W Pratz, Andrew H Wei, et al.
American Journal of Hematology
|
June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
Anne Wanquet, Thomas Prebet, Céline Berthon, et al.
Cancer
|
September 17, 2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
Jorge E Cortes, Stuart L Goldberg, Eric J Feldman, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 136) with videos related to
Sort By:
Page
of 14
Advances in Therapy
|
July 11, 2024
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2
Claire N Harrison, Alessandro M Vannucchi, Christian Recher, et al.
Emerging Infectious Diseases
|
July 22, 2015
Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
Suzanne Tavitian, Jean-Marie Peron, Françoise Huguet, et al.
Haematologica
|
July 7, 2017
Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients
Etienne De Clara, Morgane Gourvest, Hanjing Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, James S Blachly, Armin Ghobadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
Thomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Experimental Hematology & Oncology
|
September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Mary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
American Journal of Hematology
|
September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO Study
Corentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A Pollyea, Keith W Pratz, Andrew H Wei, et al.
American Journal of Hematology
|
June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
Anne Wanquet, Thomas Prebet, Céline Berthon, et al.
Cancer
|
September 17, 2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
Jorge E Cortes, Stuart L Goldberg, Eric J Feldman, et al.
Page
of 14